Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cereghino, J. J.
Right arrow Articles by Leppik, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cereghino, J. J.
Right arrow Articles by Leppik, I.
Neurology 2000;55:236-242
© 2000 American Academy of Neurology
Articles

Levetiracetam for partial seizures

Results of a double-blind, randomized clinical trial

J. J. Cereghino, MD, V. Biton, MD, B. Abou-Khalil, MD, F. Dreifuss, MD{dagger}, L. J. Gauer, I. Leppik, MD and the United States Levetiracetam Study Group*

From Oregon Health Sciences University (Dr. Cereghino), Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss
{dagger}), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis.

Address correspondence and reprint requests to Dr. James J. Cereghino, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd. CDW-3, Portland, OR 97201-3098.

OBJECTIVE: To evaluate the efficacy and safety of 500 mg bid and 1500 mg bid levetiracetam as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled, parallel-group, multicenter trial.

METHODS: The authors studied patients with uncontrolled partial seizures (minimum 12 per 12 weeks), regardless of whether they became secondarily generalized, for 38 weeks. A 12-week baseline was followed by random assignment to adjunctive therapy with placebo (n = 95), levetiracetam 1000 mg/day (n = 98), or levetiracetam 3000 mg/day (n = 101). Upward titration over 4 weeks was followed by 14 weeks of fixed dose treatment, and concluded with an 8-week medication withdrawal period or entering a follow-up study.

RESULTS: Of 294 patients randomized, 268 completed the study. Partial seizure frequency during the entire evaluation period (primary efficacy variable) was lower with levetiracetam compared to placebo (p <= 0.001 for both groups). More patients responded (defined as minimum 50% reduction in partial seizure frequency) to levetiracetam than placebo, with rates of 33.0% in the 1000 mg/day and 39.8% in the 3000 mg/day group, compared to 10.8% in the placebo group (p < 0.001). Of 199 patients receiving levetiracetam, 11 became seizure free; no patient became seizure free in the placebo group. Treatment-emergent adverse events (>=10%), mostly mild to moderate in severity, with incidences higher than placebo were asthenia, dizziness, flu syndrome, headache, infection, rhinitis, and somnolence.

CONCLUSION: Adjunctive therapy with levetiracetam was effective and well tolerated in controlling partial seizures.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Schulze-Bonhage, S Hefft, and B Oehl
Termination of complex partial status epilepticus by intravenous levetiracetam
J. Neurol. Neurosurg. Psychiatry, August 1, 2009; 80(8): 931 - 933.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. Perucca, J. Carter, V. Vahle, and F. G. Gilliam
Adverse antiepileptic drug effects: Toward a clinically and neurobiologically relevant taxonomy
Neurology, April 7, 2009; 72(14): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. U. Farooq, A. Bhatt, A. Majid, R. Gupta, A. Khasnis, and M. Y. Kassab
Levetiracetam for managing neurologic and psychiatric disorders
Am. J. Health Syst. Pharm., March 15, 2009; 66(6): 541 - 561.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
B. S. Oken
Placebo effects: clinical aspects and neurobiology
Brain, November 1, 2008; 131(11): 2812 - 2823.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Z. Koubeissi, S. Amina, I. Pita, G. K. Bergey, and M. A. Werz
Tolerability and efficacy of oral loading of levetiracetam
Neurology, May 27, 2008; 70(22_Part_2): 2166 - 2170.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Noachtar, E. Andermann, P. Meyvisch, F. Andermann, W. B. Gough, J. Schiemann-Delgado, and For the N166 Levetiracetam Study Group
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Neurology, February 19, 2008; 70(8): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. J. Meador, A. Gevins, D. W. Loring, L. K. McEvoy, P. G. Ray, M. E. Smith, G. K. Motamedi, B. M. Evans, and C. Baum
Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam
Neurology, November 27, 2007; 69(22): 2076 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. F. Berkovic, R. C. Knowlton, R. F. Leroy, J. Schiemann, U. Falter, and On behalf of the Levetiracetam N01057 Study Group
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
Neurology, October 30, 2007; 69(18): 1751 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D.G.A. Kasteleijn-Nolst Trenite, P. Genton, D. Parain, P. Masnou, B. J. Steinhoff, T. Jacobs, E. Pigeolet, A. Stockis, and E. Hirsch
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
Neurology, September 4, 2007; 69(10): 1027 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. J. Porter, A. Partiot, R. Sachdeo, V. Nohria, W. M. Alves, and on behalf of the 205 Study Group
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
Neurology, April 10, 2007; 68(15): 1197 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. J. Brodie, E. Perucca, P. Ryvlin, E. Ben-Menachem, H.-J Meencke, and for the Levetiracetam Monotherapy Study Group
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Neurology, February 6, 2007; 68(6): 402 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. I. Sirven, T. D. Fife, D. M. Wingerchuk, and J. F. Drazkowski
Second-Generation Antiepileptic Drugs' Impact on Balance: A Meta-analysis
Mayo Clin. Proc., January 1, 2007; 82(1): 40 - 47.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. R. Chabolla and Z. K. Wszolek
Pharmacologic management of seizures in organ transplant
Neurology, December 26, 2006; 67(12_suppl_4): S34 - S38.
[Abstract] [Full Text]

Home page
 NeurologyHome page
T. A. Glauser, R. Ayala, R. D. Elterman, W. G. Mitchell, C. B. Van Orman, L. J. Gauer, Z. Lu, and on behalf of the N159 Study Group
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures
Neurology, June 13, 2006; 66(11): 1654 - 1660.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Friedman and J. A. French
Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures
Neurology, February 28, 2006; 66(4): 590 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
N. Hawkins, D. Epstein, M. Drummond, J. Wilby, A. Kainth, D. Chadwick, and M. Sculpher
Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model
Med Decis Making, September 1, 2005; 25(5): 493 - 510.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. E. Mandelbaum, M. Bunch, S. L. Kugler, A. Venkatasubramanian, and J. B. Wollack
Efficacy of Levetiracetam at 12 Months in Children Classified by Seizure Type, Cognitive Status, and Previous Anticonvulsant Drug Use
J Child Neurol, July 1, 2005; 20(7): 590 - 594.
[Abstract] [PDF]

Home page
 NeurologyHome page
A. Beydoun, B. M. Uthman, A. R. Kugler, M. J. Greiner, L. E. Knapp, E. A. Garofalo, and the Pregabalin 1008-009 Study Group
Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy
Neurology, February 8, 2005; 64(3): 475 - 480.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
F. Vigevano
Topical Review: Levetiracetam in Pediatrics
J Child Neurol, February 1, 2005; 20(2): 87 - 93.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. Cavitt and M. Privitera
Levetiracetam Induces a Rapid and Sustained Reduction of Generalized Spike-Wave and Clinical Absence
Arch Neurol, October 1, 2004; 61(10): 1604 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Nicolson, S. A. Lewis, and D. F. Smith
A prospective analysis of the outcome of levetiracetam in clinical practice
Neurology, August 10, 2004; 63(3): 568 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. W. Wheless and B. F. D. Bourgeois
Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
J Child Neurol, August 1, 2004; 19(1_suppl): S39 - S48.
[Abstract] [PDF]

Home page
 NeurologyHome page
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al.
Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Neurology, April 27, 2004; 62(8): 1261 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. M. LaRoche and S. L. Helmers
The New Antiepileptic Drugs: Scientific Review
JAMA, February 4, 2004; 291(5): 605 - 614.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. W. Wheless and B. F. D. Bourgeois
Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
J Child Neurol, January 1, 2004; 19(1_suppl): S39 - S48.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
R. Coupez, R. Straetemans, G. Sehgal, A. Stockis, and Z.(S. Lu
Levetiracetam: Relative Bioavailability and Bioequivalence of a 10% Oral Solution (750 mg) and 750-mg Tablets
J. Clin. Pharmacol., December 1, 2003; 43(12): 1370 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. R. White, T. S. Walczak, I. E. Leppik, J. Rarick, T. Tran, T. E. Beniak, D. J. Matchinsky, and R. J. Gumnit
Discontinuation of levetiracetam because of behavioral side effects: A case-control study
Neurology, November 11, 2003; 61(9): 1218 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Mula, M. R. Trimble, A. Yuen, R. S.N. Liu, and J. W.A.S. Sander
Psychiatric adverse events during levetiracetam therapy
Neurology, September 9, 2003; 61(5): 704 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
D. K. Nguyen and S. S. Spencer
Recent Advances in the Treatment of Epilepsy
Arch Neurol, July 1, 2003; 60(7): 929 - 935.
[Full Text] [PDF]

Home page
 NeuroscientistHome page
O. A. C. Petroff
Book Review: GABA and Glutamate in the Human Brain
Neuroscientist, December 1, 2002; 8(6): 562 - 573.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
C. W. Bazil, A. Rose, S. Resor, B. Yapicular, and L. J. Hirsch
Levetiracetam May Be More Effective for Late-Onset Partial Epilepsy
Arch Neurol, December 1, 2002; 59(12): 1905 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. I. Sirven
Antiepileptic Drug Therapy for Adults: When to Initiate and How to Choose
Mayo Clin. Proc., December 1, 2002; 77(12): 1367 - 1375.
[Abstract] [PDF]

Home page
 NeurologyHome page
E. R. Somerville
Aggravation of partial seizures by antiepileptic drugs: Is there evidence from clinical trials?
Neurology, July 9, 2002; 59(1): 79 - 83.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. A. Glauser
Integrating clinical trial data into clinical practice
Neurology, June 25, 2002; 58(12_suppl_7): S6 - S12.
[Full Text]

Home page
 Journal of Pharmacy PracticeHome page
J. C. Chappell and H. Cohen
Frontiers in Neuropharmacotherapy Part I: Alzheimer's Disease and Epilepsy
Journal of Pharmacy Practice, June 1, 2002; 15(3): 195 - 220.
[Abstract] [PDF]

Home page
 DTBHome page
{blacktriangledown}Levetiracetam - a new drug for epilepsy
DTB, April 1, 2002; 40(4): 30 - 32.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S D Shorvon and K van Rijckevorsel
A new antiepileptic drug
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 426 - 429.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
I. E. Silverman, L. Restrepo, and G. C. Mathews
Poststroke Seizures
Arch Neurol, February 1, 2002; 59(2): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
I. E. Leppik
Three New Drugs for Epilepsy: Levetiracetam, Oxcarbazepine, and Zonisamide
J Child Neurol, January 1, 2002; 17(1_suppl): S53 - S57.
[Abstract] [PDF]

Home page
 NeurologyHome page
N. M. Katariwala, R. A.E. Bakay, P. B. Pennell, L. D. Olson, T. R. Henry, and C. M. Epstein
Remission of intractable partial epilepsy following implantation of intracranial electrodes
Neurology, October 23, 2001; 57(8): 1505 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. J. Frucht, E. D. Louis, C. Chuang, and S. Fahn
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus
Neurology, September 25, 2001; 57(6): 1112 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Y. H. Sohn, A. Kaelin-Lang, H. Y. Jung, and M. Hallett
Effect of levetiracetam on human corticospinal excitability
Neurology, September 11, 2001; 57(5): 858 - 863.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Krakow, M. Walker, C. Otoul, and J.W.A.S. Sander
Long-term continuation of levetiracetam in patients with refractory epilepsy
Neurology, June 26, 2001; 56(12): 1772 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
O. A.C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson
Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures
Neurology, March 27, 2001; 56(6): 709 - 715.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G.L. Krauss, A. Bergin, R.E. Kramer, Y.-W. Cho, and S.G. Reich
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam
Neurology, February 13, 2001; 56(3): 411 - 412.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.